Source: Eur Respir J 2014; 43: 1556-1559
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
McGoon Michael D.. Upfront triple therapy for pulmonary arterial hypertension: is three a crowd or critical mass?. Eur Respir J 2014; 43: 1556-1559

Member's Comments

No comment yet.

Related content which might interest you: Initial triple therapy in pulmonary arterial hypertension: coming of age and rejuvenated Source: Eur Respir J, 57 (1) 2004258; 10.1183/13993003.04258-2020 Year: 2021 Goal-oriented therapy in paediatric pulmonary arterial hypertension: are we ready? Source: Eur Respir J 2014; 44: 1404-1407 Year: 2014 Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension Source: Eur Respir J, 57 (1) 2001120; 10.1183/13993003.01120-2020 Year: 2021 Beyond a single pathway: combination therapy in pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 408-417 Year: 2016 Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study Source: Eur Respir J 2014; 43: 1691-1697 Year: 2014 The role of combination therapy in managing pulmonary arterial hypertension Source: Eur Respir Rev 2014; 23: 469-475 Year: 2014 Pulmonary arterial hypertension: combination therapy in the modern management era Source: Eur Respir Rev 2010 19: 348-349 Year: 2010 Optimal management of severe pulmonary arterial hypertension Source: Eur Respir Rev 2011; 20: 254-261 Year: 2011 Initial dual oral combination therapy in pulmonary arterial hypertension Source: Eur Respir J 2016; 47:1727-1736 Year: 2016 Combination therapy for pulmonary arterial hypertension: still more questions than answers Source: Eur Respir J 2004; 24: 339-340 Year: 2004 Upfront combination therapy in the treatment of scleroderma-associated pulmonary arterial hypertension: Results of an open label trial Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Learning to pair therapies and the expanding matrix for pulmonary arterial hypertension: is more better? Source: Eur Respir J 2006 Oct 01;28(4):683-686 Year: 2006 ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad Source: Eur Respir J, 51 (6) 1800848; 10.1183/13993003.00848-2018 Year: 2018 Pulmonary arterial hypertension: tailoring treatment to risk in the current era Source: Eur Respir Rev, 26 (146) 170095; 10.1183/16000617.0095-2017 Year: 2017 Pulmonary arterial hypertension: treatment options Source: International Congress 2018 – ME10 Pulmonary arterial hypertension: treatment options FULLY BOOKED Year: 2018 Challenges in the diagnosis and treatment of pulmonary arterial hypertension Source: Eur Respir Rev 2012 21: 313-320 Year: 2012 Response to exercise in patients with pulmonary arterial hypertension treated with combination therapy Source: ERJ Open Res, 7 (1) 00725-2020; 10.1183/23120541.00725-2020 Year: 2021 Thrombo-embolic pulmonary hypertension: which treatment should we choose? / Hypertension pulmonaire thrombo-embolique: quel traitement choisir ? Source: International Congress 2018 – French Programme 2018: Part II Year: 2018 Repurposing benzbromarone for pulmonary arterial hypertension: can channelling the past deliver the therapy of the future? Source: Eur Respir J, 53 (6) 1900583; 10.1183/13993003.00583-2019 Year: 2019 ?-blockers in pulmonary arterial hypertension: generation might matter Source: Eur Respir J 2016; 47: 682-684 Year: 2016